Clinical trial Recruiting at 1 site Observational Ages 18 to 45

How spicy compounds affect blood flow in the feet

Official title: The Role of Transient Receptor Potential Channels in Diabetic Peripheral Neuropathy

Run by Universitaire Ziekenhuizen KU Leuven · NCT07237022 · Data updated 2026-11-12

This research will see if applying cinnamaldehyde, AITC, or capsaicin to the feet of healthy adults changes skin blood flow and whether those responses are consistent across doses, between feet, and across visits.

Quick facts

Study typeObservational
Ages18 Years to 45 Years
SexAll
Enrollment20 (estimated)
SponsorUniversitaire Ziekenhuizen KU Leuven
Academic / other
Locations1 site (Leuven)
StatusRecruiting
StartedOctober 8, 2025
Main results expectedMay 31, 2026
Study endsAugust 31, 2026
Registry record updatedNovember 19, 2025
Trial IDNCT07237022 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal participants are healthy white adults aged 18–45 who are non-smokers, have a BMI of 18–30 kg/m², and have no significant medical history or regular medications that could confound results.

Probably not a fit

People with active illnesses, significant allergies, regular medication use that might affect vascular responses, smokers, pregnant or breastfeeding women, or those outside the specified age or BMI ranges are unlikely to be eligible or to gain direct benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study applying three topical TRP-activating compounds (cinnamaldehyde, allyl isothiocyanate, and capsaicin) to the skin of the feet in healthy volunteers. Vascular responses will be measured over time and across multiple doses, and the study will test reproducibility between the left and right foot and between study periods. Eligible participants are healthy white adults 18–45 years old, non-smokers, with BMI between 18 and 30 kg/m². The work is conducted at a single center using non-invasive measurements to characterize time course, dose-response, and inter-period variability of the skin blood flow response.

Why it matters

Potential benefit: If successful, the results could clarify how TRP channel activation changes skin blood flow and help guide development of topical diagnostics or treatments for peripheral nerve or vascular conditions.

How similar studies have gone: Previous experimental studies using capsaicin and other TRP agonists have reliably produced local vasodilatory responses in healthy volunteers, so this approach builds on established pharmacologic effects.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Subject is a white male or female ≥18 and ≤45 years of age
2. Subject is a non-smoker for at least 6 months prior to the start of the study
3. Subject has a body mass index (BMI) between 18-30 kg/m²
4. Subject is judged to be in good general health on the basis of medical history, physical examination and vital signs
5. Subject understands the procedures and agrees to participate in the study by giving written informed consent.

Exclusion Criteria:

1. Subject has a history of any illness or disorder which, in the investigator's opinion, might confound the results of the study
2. Subject has a history of significant severe (drug) allergies
3. Subject is a female who is pregnant, breast-feeding or intends to become pregnant, or is of child-bearing potential and is not using an adequate contraceptive method
4. Subject uses any prescription or non-prescription drugs on a regular basis which, in the investigator's opinion, might confound the results of the study
5. Subject currently uses lotions, oils, depilatory preparations, makeup, or other topical treatments on the feet on a regular basis which cannot be discontinued for the duration of the study
6. Subject has eczema, scleroderma, psoriasis, dermatitis or keloids, tumors, ulcers, burns, skin flaps or grafts on the volar surface of the forearm or the dorsum of the feet, or any other skin abnormality that, in the opinion of the investigator, may interfere with the study assessments
7. Subject has excessive hair growth on the volar surface of the forearms or the dorsum of the feet
8. Subject has any of the following vital sign measurements at screening after at least 10 minutes of supine rest: Heart Rate \<40 or \>100 beats/min, Diastolic Blood Pressure \<50 or \>90 mmHg, Systolic Blood Pressure \<90 or \>140 mmHg
9. Subject is unable to refrain from drinking caffeinated beverages (e.g. coffee, tea, cola, …) 24 hours prior to each study visit. Subject is unable to limit their intake of caffeinated beverages to ≤4 cups a day throughout the study
10. Subject is unable to refrain from drinking alcohol 24 hours prior to each study visit, is currently a regular user of illegal drugs, or has a history of substance abuse (including alcohol)
11. Subject is currently participating or has been involved in testing an investigational drug in another clinical study within the last 4 weeks
12. Subject is in a situation or has a condition which, in the opinion of the investigator, may interfere with safe and optimal participation in the study

Where it's running

  • Center for Clinical Pharmacology
    Leuven, Belgium
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.